% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • fudfighter4 fudfighter4 Feb 4, 2013 11:48 AM Flag

    Fortune favours the brave - but rarely the gullible

    Continually averaging down in a biotech is the right strategy - if you've found the right biotech.

    From the Genta board a few years ago -

    "Time to buy?

    Good to average down, especially at these prices,but I suspect lower.
    I bought last @7.19, hoping for a trade and a rally,GNTA really never saw it.
    Is our bear market rally over? Friday suggested it might be, if volume confirms this week, then have cash to buy this gem.
    Still a news driven biotech, there is always chance of a quick bubble to make money also but I stand by my... buy it, tuck it away, don't look!,come back in 2 years
    Good Luck to all Longs"

    and -

    "The stratagy works because it is after the fear,the shorts and the ride on the biotech rollercoaster.(NDA,FDA etc)

    Analysts ability to "move" a stock will be overtaken by what will be the marketplace in 2 years.(look at post 70's bear market for historical perspective) A marketplace of valuations and earnings.
    GNTA IMHO will have them....soooooooooo But it tuck it away dont'LOOK !come back in 2 years
    Good Luck to all LOngs"

    Genta gained 50% on Friday - from $0.0002 to $0.0003. Let's hope Terry took full advantage of his latest opportunity to average down, by snapping up an extra million shares for $200.

    When a leading contender for the title of Worst Investor in Biotech offers the following warning about INSM -

    "YTD 25% "the short since stop $4"

    - let his track record speak for itself.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
14.04-0.03(-0.21%)Oct 21 4:00 PMEDT